MedTrace Logo

Hydroxychloroquine in COVID-19 Patients

NCT04394442 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-05-19

No results posted yet for this study

Summary

Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

Conditions

Interventions

DRUG

Hydroxychloroquine

400mg BD first day then 200 mg BD for 5 days

Sponsors & Collaborators

  • Samah Lutfy

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-21
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04394442 on ClinicalTrials.gov